Zidebactam

Summary

Zidebactam (CHEMBL4533605) is a phase-3 clinical-stage small molecule; indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 391.4 Da · C13H21N5O7S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4533605
Name	Zidebactam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	77846445
Molecular formula	C13H21N5O7S
Molecular weight	391.4
InChIKey	YCZPXRQPDCXTIO-BBBLOLIVSA-N

SMILES: C1C[C@H](CNC1)C(=O)NNC(=O)[C@@H]2CC[C@@H]3CN2C(=O)N3OS(=O)(=O)O

IUPAC name: [(2S,5R)-7-oxo-2-[[[(3R)-piperidine-3-carbonyl]amino]carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate

Also known as: WCK 5107, WCK-5107, WCK5107, Zidebactam, Zidebactam, (-)-, ZIDEBACTAM

Patent coverage: 44 distinct patent families (99 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	1	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05645757	PHASE1	COMPLETED	Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).